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Inclusion of albuminuria in hypertension and heart guide-
lines. The current recommendations by all United States guide-
line committees, including the American Diabetes Association
and the JNC 7, include screening for microalbuminuria in those
with diabetes or evidence of kidney disease, but not the gen-
eral population. Internationally, both the Canadian and Eu-
ropean Guidelines have concurred with this approach. This
recommendation is due in part to the findings from long-term
outcome studies that measurement of microalbuminuria, while
a strong predictor of cardiovascular risk, fails to shows change
in CV events if reduced. Unfortunately, this conclusion may be
wrong because no randomized trial has examined the question
of whether a reduction in microalbuminuria does correlate with
a reduction in CV events. Thus, we don’t know the answer to
this question. Additionally, a recent cost-effective analysis was
just published, suggesting it is not worth measuring urinary al-
bumin because it is too expensive for the information obtained.
Unfortunately, these conclusions were based on the same faulty
logic that relates changes in microalbuminuria to cardiovascu-
lar events. It is clear that microalbuminuria is a cardiovascular
risk factor, acknowledged by both the JNC 7 and the European
Guidelines. Moreover, presence of microalbuminuria correlates
strongly with elevated levels of C-reactive protein and abnor-
mal vascular responsiveness to vasodilating stimuli. Thus, its
presence indicates abnormal responses by vascular tissue, per-
haps due to underlying inflammatory responses. Every clinical
trial that has assessed changes in albuminuria as a secondary
end point with clinical outcomes has shown a strongly positive
correlation between reduction in albuminuria and greater pro-
tection of a given end organ; this effect is, in part, independent
of blood pressure reduction. Thus, what is needed is a clinical
trial in people at high cardiovascular risk, such as those in the
INVEST or ALLHAT trials where the primary end point is
change in albuminuria and its relationship to cardiovascular
outcomes. Likewise, a cardiovascular primary end point could
relate to the secondary end point of changes in microalbumin-
uria, and the latter powered appropriately to make stronger
statements about albuminuria and cardiovascular outcomes.
With this data, guidelines can then make much strong state-
ments about intervention on this marker of risk.
The current recommendations by guideline commit-
tees around the world, including the American Diabetes
Association, National Kidney Foundation, the Canadian
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Society of Hypertension, the European Society of Hy-
pertension, European Society of Cardiology, as well as
the Joint National Committee Report (JNC) 7, include
screening for albuminuria in patients with diabetes or ev-
idence of kidney disease, but not the general population
[1–5]. This recommendation is due to overwhelming epi-
demiologic evidence that presence of microalbuminuria
is associated with a high risk for cardiovascular events,
and that the greater the level of albuminuria, the greater
the risk for a cardiovascular event [4, 6–9].
Microalbuminuria is also associated with a failure of
nocturnal drops in arterial pressure, insulin resistance,
as well as abnormal vascular responsiveness to a variety
of stimuli [10–12]. Thus, its presence indicates abnormal
responses by vascular tissue perhaps due to underlying
inflammatory responses. It correlates strongly with ele-
vated levels of C-reactive protein (CRP), a well-known
cardiovascular marker of risk [13, 14]. Taken together,
these data support the concept that microalbuminuria is
a strong predictor of cardiovascular risk; however, it has
never been assessed in a clinical trial with regard to re-
duction in level and resultant cardiovascular outcomes.
Because we can’t answer this question, guideline com-
mittees are hesitant to recommend general screening for
the population.
FUTURE CONSIDERATIONS
Guidelines are evidence-based primarily on outcomes,
and not markers of disease progression. This is why rec-
ommendations for specific goals of LDL cholesterol and
blood pressure did not appear until data from both epi-
demiologic studies as well as randomized trials demon-
strated the importance of manipulating such markers to
affect cardiovascular outcomes. Albuminuria lacks ran-
domized trial data with regard to cardiovascular out-
comes; its strength as a marker of risk is solely based
on post hoc analyses of trials and epidemiologic analyses
of databases.
A recent cost-effective analysis suggests that it is not
worth measuring urinary protein excretion in the general
population because it is too expensive for the informa-
tion obtained in people with hypertension and absence of
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diabetes or kidney disease [15]. Thus, for manipulation
of albuminuria to be considered in future guidelines it
is imperative that a clinical trial that focuses on changes
in albuminuria in conjunction with cardiovascular out-
comes be performed. Clinical trial data should be accu-
mulated from people at high cardiovascular risk, such as
those studied in ALLHAT, INVEST, CONVINCE, or
LIFE trials, where a change in albuminuria is powered
to a reduction in cardiovascular end points. Moreover,
these outcome trials will have to show that reductions in
albuminuria account for reduction in cardiovascular risk
that cannot be totally accounted for by lowering of blood
pressure.
While there are multiple renal outcome studies that
clearly show a relationship between reductions in pro-
teinuria and slowed progression of disease [16, 17], an
effect partially independent of blood pressure reduction,
no such data exist in cardiovascular outcome trials. Un-
fortunately, the renal trials are underpowered for car-
diovascular outcomes. With such data available, future
guidelines can then make much stronger statements and
recommendations about intervention on this marker of
cardiovascular risk.
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